LINCOLN vs WOCKPHARMA: Stock Comparison

Lincoln Pharmaceuticals Limited vs Wockhardt Ltd

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Lincoln Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Wockhardt Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lincoln Pharmaceuticals Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LINCOLN is more favourable on 9 of 13 scored metrics and WOCKPHARMA on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹1,166 Cr
P/E Ratio
LINCOLN has a lower P/E
13.64x vs 144.46x
P/B Ratio
LINCOLN has a lower P/B
1.58x vs 6.23x
EPS
LINCOLN has higher earnings per share
₹43.87 vs ₹13.1
Dividend Yield
LINCOLN has a higher dividend yield
0.29% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 11.4%
EPS Growth (TTM YoY)
LINCOLN has faster EPS growth
0.6% vs 0%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs 11.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLINCOLNWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLINCOLNWOCKPHARMA
Live Price₹581.35₹1,867
Day Change-2.87%-1.55%
Volume26,4847.13 L
52-Week High₹770₹2,422.3
52-Week Low₹440₹1,086.7
Distance from 52W High-24.5%-22.92%

Valuation

MetricLINCOLNWOCKPHARMA
Market Cap₹1,166 Cr₹30,362 Cr
P/E Ratio13.64x144.46x
P/B Ratio1.58x6.23x
EPS₹43.87₹13.1
Book Value₹378.34₹304
Dividend Yield0.29%0%

Growth

MetricLINCOLNWOCKPHARMA
Revenue Growth (TTM YoY)11.4%26%
EPS Growth (TTM YoY)0.6%0%
Qtr Sales Growth11.4%29.9%
Qtr Profit Growth0.43%688%

Profitability & Leverage

MetricLINCOLNWOCKPHARMA
ROE12.3%6.11%
ROCE16.3%7.55%
Net Margin13.1%3.3%
Operating Margin14.6%19.3%
Debt to Equity0.01x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricLINCOLNWOCKPHARMA
Promoter Holding49.78%49.08%
FII Holding4.6% 0.59 pp7.09% 0.1 pp
DII Holding0.27% 0.82 pp10.96% 0.41 pp
Public Holding45.36% 1.42 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lincoln Pharmaceuticals Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.